Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder

Area of Science:

• Reproductive Immunology
• Maternal-Fetal Medicine
• Autoimmune Disorders

Background:

• Obstetric antiphospholipid syndrome (APS) is a distinct clinical entity characterized by specific pregnancy morbidities.
• Antiphospholipid antibodies (aPLs) are implicated, but their pathogenic mechanisms in pregnancy extend beyond thrombosis.
• Current understanding of aPLs' role in obstetric complications and potential non-thrombotic effects is incomplete.

Purpose of the Study:

• To delineate the distinct features of obstetric APS.
• To explore pathogenic mechanisms of aPLs in pregnancy beyond thrombotic events.
• To review current treatment efficacy and investigate novel therapeutic strategies.

Main Methods:

• Review of obstetric complications defining APS.
• Analysis of proposed pathogenic mechanisms including complement activation and direct placental effects.
• Evaluation of standard treatment (aspirin and heparin) and ongoing research into alternative therapies.

Main Results:

• Obstetric APS is defined by recurrent miscarriages, fetal death, or premature birth due to specific conditions.
• Pathogenic mechanisms may involve placental complement activation and direct aPL effects on placental development, not solely thrombosis.
• Standard therapy is effective but complications persist in up to 20% of patients.

Conclusions:

• Obstetric APS requires understanding of non-thrombotic pathogenic pathways.
• Further research into novel therapies targeting aPL binding or effects at the placental level is crucial.
• Investigating the impact of maternal autoantibodies on fetal/neonatal outcomes remains important.